Kyongbo Pharmaceutical Co Ltd (KO:214390) — Stock Price
Kyongbo Pharmaceutical Co Ltd (KO:214390) is currently trading at ₩5300.00 KRW, up 1.15% today. Over the past 52 weeks, shares have ranged between ₩4825.00 and ₩8550.00. This page tracks Kyongbo Pharmaceutical Co Ltd's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Kyongbo Pharmaceutical Co Ltd market capitalisation.
Kyongbo Pharmaceutical Co Ltd (214390) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Kyongbo Pharmaceutical Co Ltd's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Kyongbo Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Kyongbo Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩238.56 Billion | ₩216.36 Billion | ₩196.26 Billion | ₩170.66 Billion | ₩215.29 Billion |
| Cost of Revenue | ₩156.14 Billion | ₩153.28 Billion | ₩151.85 Billion | ₩135.30 Billion | ₩162.82 Billion |
| Gross Profit | ₩82.42 Billion | ₩63.08 Billion | ₩44.42 Billion | ₩35.36 Billion | ₩52.46 Billion |
| Research & Development | ₩5.31 Billion | ₩3.65 Billion | ₩3.08 Billion | ₩5.05 Billion | ₩6.24 Billion |
| SG&A | ₩47.04 Billion | ₩35.78 Billion | ₩1.91 Billion | ₩2.29 Billion | ₩2.93 Billion |
| Total Operating Expenses | ₩228.10 Billion | ₩210.81 Billion | ₩43.03 Billion | ₩41.99 Billion | ₩43.80 Billion |
| Operating Income | ₩10.45 Billion | ₩5.54 Billion | ₩1.39 Billion | ₩-4.60 Billion | ₩5.68 Billion |
| EBITDA | — | — | ₩13.12 Billion | ₩8.16 Billion | ₩18.27 Billion |
| EBIT | — | — | ₩1.39 Billion | ₩-4.60 Billion | ₩5.68 Billion |
| Interest Expense | ₩4.29 Billion | ₩3.40 Billion | ₩1.67 Billion | ₩1.18 Billion | ₩1.31 Billion |
| Income Before Tax | ₩4.90 Billion | ₩2.17 Billion | ₩-614.84 Million | ₩-9.93 Billion | ₩14.03 Billion |
| Income Tax Expense | — | — | ₩-1.23 Billion | ₩-2.44 Billion | ₩4.63 Billion |
| Net Income | ₩4.64 Billion | ₩2.97 Billion | ₩610.59 Million | ₩-7.50 Billion | ₩9.40 Billion |
Kyongbo Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Kyongbo Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩283.89 Billion | ₩266.31 Billion | ₩240.54 Billion | ₩236.98 Billion | ₩253.24 Billion |
| Total Current Assets | ₩151.94 Billion | ₩135.90 Billion | ₩116.33 Billion | ₩111.17 Billion | ₩138.19 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩2.00 Billion | ₩870.00 Million | ₩870.00 Million | ₩-1.16 Billion | ₩9.54 Billion |
| Net Receivables | ₩51.62 Billion | ₩56.16 Billion | ₩51.66 Billion | ₩49.21 Billion | ₩55.04 Billion |
| Inventory | ₩90.59 Billion | ₩70.66 Billion | ₩57.44 Billion | ₩57.67 Billion | ₩62.17 Billion |
| Property, Plant & Equipment | — | — | ₩93.92 Billion | ₩95.68 Billion | ₩90.10 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩137.73 Billion | ₩121.92 Billion | ₩96.84 Billion | ₩91.28 Billion | ₩97.18 Billion |
| Total Current Liabilities | ₩132.66 Billion | ₩118.26 Billion | ₩95.57 Billion | ₩88.81 Billion | ₩93.76 Billion |
| Long-term Debt | — | ₩45.00 Million | ₩135.00 Million | ₩225.00 Million | ₩315.00 Million |
| Net Debt | ₩85.19 Billion | ₩68.75 Billion | ₩58.16 Billion | ₩52.30 Billion | ₩51.83 Billion |
| Total Stockholder Equity | ₩146.15 Billion | ₩144.38 Billion | ₩143.70 Billion | ₩145.70 Billion | ₩156.06 Billion |
| Retained Earnings | ₩98.33 Billion | ₩96.03 Billion | ₩94.70 Billion | ₩94.59 Billion | ₩104.21 Billion |
Kyongbo Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Kyongbo Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩149.12 Million | ₩4.84 Billion | ₩10.13 Billion | ₩17.97 Billion | ₩20.80 Billion |
| Capital Expenditures | ₩13.18 Billion | ₩10.88 Billion | ₩13.18 Billion | ₩18.32 Billion | ₩12.44 Billion |
| Free Cash Flow | ₩-13.03 Billion | ₩-6.03 Billion | ₩-3.06 Billion | ₩-355.61 Million | ₩8.36 Billion |
| Investing Cash Flow | — | — | ₩-14.88 Billion | ₩-16.17 Billion | ₩-19.68 Billion |
| Financing Cash Flow | — | — | ₩6.59 Billion | ₩-9.22 Billion | ₩4.42 Billion |
| Dividends Paid | ₩-1.20 Billion | ₩-1.20 Billion | ₩1.20 Billion | ₩2.39 Billion | ₩2.39 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩12.41 Billion | ₩11.70 Billion | ₩11.94 Billion | ₩12.76 Billion | ₩12.59 Billion |
| Change in Cash | ₩-349.31 Million | ₩-1.87 Billion | ₩2.06 Billion | ₩-7.15 Billion | ₩4.67 Billion |
Kyongbo Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Kyongbo Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 126.82 | — | — |
| Jun 30, 2025 | -72.54 | — | — |
| May 15, 2025 | -29.06 | — | — |
| Mar 18, 2025 | 73.27 | — | — |
| Nov 14, 2024 | 45.23 | — | — |
| Aug 14, 2024 | 6.55 | — | — |
| Apr 26, 2024 | 69.01 | — | — |
| Jan 29, 2024 | 85.21 | — | — |